More Vaccines Restructuring As Daiichi's Oncology Pivot Gains Momentum
Daiichi Sankyo makes further vaccine business restructuring moves as it emphasizes oncology amid global generic challenges to its former big seller olmesartan.
You may also be interested in...
Daiichi Sankyo unveils further restructuring moves, this time mainly in its R&D functions in Japan, as part of an ongoing strategic pivot towards oncology.
Big cut in mid-term profit outlook hits Daiichi Sankyo shares but company says it is reallocating more to R&D to accelerate the strategic build-out of its oncology franchise.
In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.